<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892099</url>
  </required_header>
  <id_info>
    <org_study_id>2009P-000398</org_study_id>
    <secondary_id>1R01DK084974-01</secondary_id>
    <nct_id>NCT00892099</nct_id>
  </id_info>
  <brief_title>DIVINE: Dialysis Infection and Vitamin D In New England</brief_title>
  <official_title>DIVINE: Dialysis Infection and Vitamin D In New England</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection is the second-leading cause of death in individuals requiring dialysis treatment
      for kidney failure. New research suggests the high risk of infection may be due in part to
      low levels of vitamin D, which are extremely common in kidney disease. This study is
      designed to determine safe and effective ways to raise vitamin D levels while monitoring
      effects on the immune system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that a profound deficiency of nutritional vitamin D (25-hydroxyvitamin D,
      25D) in end-stage renal disease (ESRD) leads to an altered immune response, predisposing to
      early morbidity and mortality from infection, the second-leading cause of death in ESRD. In
      addition to impaired renal synthesis of the hormonal form of vitamin D
      (1,25-dihydroxyvitamin D; 1,25D), ESRD is accompanied by near universal insufficiency of
      25D. In-vitro, ex-vivo, and retrospective human studies by our group and others suggest that
      25D (and not 1,25D) is intimately linked to immune defense via alterations in the production
      of inflammatory cytokines and critical antimicrobial peptides including cathelicidin, which
      we have shown to identify ESRD subjects at risk for infection-related mortality.
      Ergocalciferol, which is rapidly converted to 25D, is the most widely available form of
      nutritional vitamin D in the US, yet guidelines to treat ESRD patients with nutritional
      vitamin D are absent because of limited data supporting its efficacy, safety, and biological
      effects in this population. To determine effective and safe doses of ergocalciferol in ESRD,
      we will perform a double blind placebo controlled randomized trial in 120 incident
      hemodialysis patients (40/arm x 3) with 25D levels &lt; 30ng/ml, comparing two ergocalciferol
      dosing regimens (50,000 IU/week and 50,000 IU/month) and an identically appearing placebo.
      The primary outcome will be correction of vitamin D insufficiency (25D &gt;30 ng/ml) at 12
      weeks. Serum calcium and phosphate levels will be measured every 4 weeks to assess safety,
      and blood cytokine and cathelicidin levels will be measured every 4 weeks to determine
      biological responses. To examine biological effects in greater detail, a subset of subjects
      from each arm of the study will be further analyzed with serial macrophage gene expression
      profiles and whole blood cytokine profiles following ex-vivo stimulation with
      pro-inflammatory mediators (e.g., killed S. aureus). These experiments will inform us on how
      individuals with ESRD, based on their vitamin D status and the treatment they receive, may
      respond to infection. Laboratory measures will continue for 12 weeks. Clinical follow-up and
      monitoring for infection-associated events (including antibiotic use, rates of bacteremia,
      and sepsis) will continue for 20 weeks. This pilot trial addressing a significant unmet need
      in nephrology will involve basic, translational, and clinical investigators experienced in
      vitamin D research, infection and inflammation, and in trials involving ESRD subjects. These
      data will provide an important foundation for designing future clinical trials rigorously
      assessing the effect of nutritional vitamin D on infectious and other outcomes in ESRD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Serum 25D Level</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokine Profiles</measure>
    <time_frame>every 4 weeks for 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium</measure>
    <time_frame>every 4 weeks for 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Phosphate</measure>
    <time_frame>every 4 weeks for 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parathyroid Hormone</measure>
    <time_frame>Every 4 weeks for 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 1,25-dihydroxyvitamin D Levels</measure>
    <time_frame>every 4 weeks for 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cathelicidin</measure>
    <time_frame>every 4 weeks for 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Hospitalizations and Mortality</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious Hospitalizations and Mortality</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Hospitalizations and Mortality</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>High Dose Ergocalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives 50,000 IU of ergocalciferol weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Ergocalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives 50,000 IU of ergocalciferol per month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receives no ergocalciferol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergocalciferol</intervention_name>
    <description>50,000 IU tablet given weekly</description>
    <arm_group_label>High Dose Ergocalciferol</arm_group_label>
    <other_name>vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergocalciferol</intervention_name>
    <description>50,000 IU tablet given monthly</description>
    <arm_group_label>Low Dose Ergocalciferol</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Age â‰¥ 18 years

          -  Initiating chronic hemodialysis 3x/wk at Massachusetts General Hospital, Brigham and
             Women's Hospital or Beth Israel Deaconess Medical Center with planned transfer to
             Massachusetts chronic facility

          -  Serum 25D &lt; 32 ng/ml

          -  Corrected serum calcium &lt; 10.2 mg/dl

          -  Serum phosphate &lt; 5.5 mg/dl

          -  Serum albumin &gt; 3 g/dL

          -  Informed consent

        Exclusion Criteria

          -  Pregnant or breastfeeding

          -  Women of childbearing potential not practicing one of the following measures of birth
             control: double-barrier method, hormonal contraceptives for at least 3 months prior
             to and during study, monogamous relationship with vasectomized partner, total
             abstinence from sexual intercourse with men during study.

          -  HIV positive

          -  History of allergic reaction to ergocalciferol

          -  Investigator considers subject unsuitable for any reason
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Thadhani, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bhan I, Camargo CA Jr, Wenger J, Ricciardi C, Ye J, Borregaard N, Thadhani R. Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults. J Allergy Clin Immunol. 2011 May;127(5):1302-4.e1. doi: 10.1016/j.jaci.2010.12.1097. Epub 2011 Feb 9.</citation>
    <PMID>21310475</PMID>
  </reference>
  <results_reference>
    <citation>Ishir Bhan, Dorothy A Dobens, Caitlin A. Trottier, Julia Beth Wenger, Hector Tamez, Joseph James Deferio, Kathryn J. Lucchesi, Ravi I. Thadhani. The DIVINE Trial: Dialysis Infection and Vitamin D in New England J. Am. Soc. Nephrol 24:2013 (Abstract: SA-PO1082)</citation>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 21, 2015</lastchanged_date>
  <firstreceived_date>April 30, 2009</firstreceived_date>
  <firstreceived_results_date>May 22, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ravi Thadhani</investigator_full_name>
    <investigator_title>Director of Clinical Research in Nephrology</investigator_title>
  </responsible_party>
  <keyword>end stage renal disease</keyword>
  <keyword>hemodialysis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose Ergocalciferol</title>
          <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Ergocalciferol</title>
          <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>replocated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prolonged hospitalization</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no further details</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>kidney function recovered</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Ergocalciferol</title>
          <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Ergocalciferol</title>
          <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="36"/>
                <measurement group_id="B4" value="105"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53" spread="17"/>
                <measurement group_id="B2" value="58" spread="16"/>
                <measurement group_id="B3" value="59" spread="17"/>
                <measurement group_id="B4" value="57" spread="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="7"/>
                <measurement group_id="B4" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="29"/>
                <measurement group_id="B4" value="82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="30"/>
                <measurement group_id="B4" value="90"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="31"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="22"/>
                <measurement group_id="B4" value="66"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>25(OH) vitamin D</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="21.8" spread="7"/>
                <measurement group_id="B2" value="22.3" spread="6.5"/>
                <measurement group_id="B3" value="21.7" spread="7.3"/>
                <measurement group_id="B4" value="21.9" spread="6.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum 25D Level</title>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ergocalciferol</title>
            <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum 25D Level</title>
            <units>ng/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50.4" spread="15.7"/>
                  <measurement group_id="O2" value="38.4" spread="12.2"/>
                  <measurement group_id="O3" value="26.6" spread="11.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cytokine Profiles</title>
        <time_frame>every 4 weeks for 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Calcium</title>
        <time_frame>every 4 weeks for 12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Phosphate</title>
        <time_frame>every 4 weeks for 12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parathyroid Hormone</title>
        <time_frame>Every 4 weeks for 12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum 1,25-dihydroxyvitamin D Levels</title>
        <time_frame>every 4 weeks for 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cathelicidin</title>
        <time_frame>every 4 weeks for 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Hospitalizations and Mortality</title>
        <time_frame>1 year</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infectious Hospitalizations and Mortality</title>
        <time_frame>1 year</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Hospitalizations and Mortality</title>
        <time_frame>1 year</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High Dose Ergocalciferol</title>
          <description>Receives 50,000 IU of ergocalciferol weekly
Ergocalciferol: 50,000 IU tablet given weekly</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Ergocalciferol</title>
          <description>Receives 50,000 IU of ergocalciferol per month
Ergocalciferol: 50,000 IU tablet given monthly</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Receives no ergocalciferol
Placebo: Placebo equivalent of ergocalciferol, given weekly as one tablet</description>
        </group>
      </group_list>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated PTH</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting/diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="36"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Low albumin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated phosphorus</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="36"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Elevated calcium</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Elevated potassium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Elevated white blood count</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="36"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ishir Bhan</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-3934</phone>
      <email>ibhan@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
